Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
Alexandra L BixbyLinda FitzgeraldJeong M ParkDaniel R KaulSarah TischerPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2021)
VGCV 900 mg/day for 180 days had higher rates of hematologic adverse effects resulting in frequent treatment interruptions. However, the occurrence of two cases of GCV-resistant CMV disease raises concerns about routinely using low-dose VGCV prophylaxis.